Key result
The addition of metolazone to furosemide significantly increased the mean hourly urine output rate from 11.24 cc/hr to 33.20 cc/hr in admitted patients with Cardiorenal Syndrome.
Why the study?
Furosemide can be ineffective due to diuretic resistance, and metolazone was newly introduced in the authors' country, warranting evaluation of the combination in Cardiorenal Syndrome.
Does the addition of metolazone to furosemide improve urine output in admitted patients with cardiorenal syndrome?
Observational (n=46)
No
Does the addition of metolazone to furosemide improve urine output in admitted patients with cardiorenal syndrome?
The addition of metolazone to furosemide significantly improves short-term diuresis in admitted patients with cardiorenal syndrome without causing significant electrolyte derangements.
May support sequential nephron blockade for diuresis in cardiorenal syndrome; leaves open need for randomized confirmation before practice change.
Background: Diuretics are considered one of the essential drugs in the management, wherein Furosemide is usually given. But in some cases, it can be ineffective due to diuretic resistance. Metolazone is a thiazide-like diuretic, can be combined with loop diuretics to control volume overload. Since the drug is just newly introduced in our country, this study examines the immediate effect of Metolazone-Furosemide combination and possible adverse reactions in patients with Cardiorenal Syndrome.
No takes yet. Share an insight, caveat, or question.
Bataclan RP (2019) conducted an observational in Cardiorenal Syndrome (n=46). Metolazone and Furosemide combination vs. Furosemide alone was evaluated on Net hourly urine output rate (p=<0.01). The addition of metolazone to furosemide significantly increased the mean hourly urine output rate from 11.24 cc/hr to 33.20 cc/hr in admitted patients with Cardiorenal Syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: